Grebely Jason, Genoway Krista A, Raffa Jesse D, Dhadwal Gurbir, Rajan Tasleem, Showler Grey, Kalousek Kate, Duncan Fiona, Tyndall Mark W, Fraser Chris, Conway Brian, Fischer Benedikt
Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, BC, Canada.
Drug Alcohol Depend. 2008 Jan 11;93(1-2):141-7. doi: 10.1016/j.drugalcdep.2007.09.008. Epub 2007 Nov 9.
Illicit drug users account for the majority of cases of HCV infection in the developed world, but few have received treatment.
We evaluated barriers to initiating HCV treatment -- including general treatment willingness -- and factors associated with these among HCV infected illicit drug users. Participants were recruited via convenience sampling from two community clinics in Canada. Individuals age >18 years with a history of illicit drug use completed interviewer-administered surveys. Those reporting positive HCV testing underwent additional questioning on willingness, uptake and barriers to treatment for HCV.
Of 188 HCV positive illicit drug users, 16% (n=30) had received treatment for HCV. Factors associated with a decreased treatment uptake included current heroin use and HIV/HCV co-infection. Among those not having received therapy, 77% (117/153) indicated a willingness to receive HCV treatment. Factors associated with treatment willingness included not being infected with HIV, having not recently used drugs by injection and having reported physical health problems. Among those not having sought HCV treatment (n=107), the major reasons for not doing so were: lack of information about HCV or knowledge that treatment was available (23%), the absence of symptoms (20%) and the perceived side effects of treatment (14%).
Among illicit drug users attending inner city clinics, we have observed a low uptake of HCV treatment, but a high willingness to receive therapy. An increased focus on improving education about the long-term consequences of HCV and the availability of effective treatment are important components for expanding HCV treatment among illicit drug users.
在发达国家,非法药物使用者占丙型肝炎病毒(HCV)感染病例的大多数,但接受治疗的人数很少。
我们评估了启动HCV治疗的障碍——包括总体治疗意愿——以及在感染HCV的非法药物使用者中与之相关的因素。通过便利抽样从加拿大的两家社区诊所招募参与者。年龄大于18岁且有非法药物使用史的个体完成了由访谈员进行的调查。那些报告HCV检测呈阳性的人接受了关于HCV治疗意愿、接受情况和障碍的额外询问。
在188名HCV阳性的非法药物使用者中,16%(n = 30)接受过HCV治疗。与治疗接受率降低相关的因素包括当前使用海洛因以及HIV/HCV合并感染。在未接受治疗的人中,77%(117/153)表示愿意接受HCV治疗。与治疗意愿相关的因素包括未感染HIV、近期未通过注射使用药物以及报告有身体健康问题。在未寻求HCV治疗的人(n = 107)中,未这样做的主要原因是:缺乏关于HCV的信息或不知道有治疗方法(23%)、没有症状(20%)以及认为治疗有副作用(14%)。
在城市中心诊所就诊的非法药物使用者中,我们观察到HCV治疗的接受率较低,但接受治疗的意愿较高。更加注重改善关于HCV长期后果的教育以及有效治疗的可及性是扩大非法药物使用者中HCV治疗的重要组成部分。